Leung 2011.

Methods	Retrospective chart review.
Participants	15 children (median age 3.6 years) with stage 4 (HR) disease with 131I‐MIBG‐avid lesions at initial diagnosis.
Interventions	All children received 131I‐MIBG therapy (14 had 1 infusion; 1 had 2 infusions). 14 131I‐MIBG‐therapies were administered as part of the conditioning regimen for HSCT. Lugol's solution was given for thyroid protection. For 131I‐MIBG therapy administered as curative treatment, the dose range was 9‐12.9 mCi/kg, with median dose of 12 mCi/kg. Carboplatin, etoposide and melphalan was given 7‐10 days after MIBG treatment as conditioning for HSCT.
Outcomes	At a median follow‐up of 1.2 years (range 0 to 7), 5/14 children receiving therapeutic 131I‐MIBG treatment relapsed (36%) and 4 of them died (7%). The estimated 2‐year overall survival was 12.8% and EFS was 15.3%. 6 children (43%) developed primary hypothyroidism with elevation of TSH at 5 months to 1 year after treatment and 3 required thyroxine replacement. No child experienced liver derangement immediately after 131I‐MIBG treatment.
Notes	Overlap in children with Leung 2013 is very likely. This study has not been published in full text (as of 16 May 2016), but was presented at the Societé International Oncologie et Pediatrie (International Society of Paediatric Oncology) conference 2011.